Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

177 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunodeficiency and intrinsic IFN resistance are associated with viral breakthrough to HCV therapy in HIV-coinfected patients.
Nussenblatt V, McLaughlin M, Rehm CA, Lempicki RA, Brann T, Yang J, Proschan M, Highbarger HC, Dewar RL, Imamichi T, Koratich C, Neumann AU, Masur H, Polis MA, Kottilil S. Nussenblatt V, et al. Among authors: polis ma. AIDS Res Hum Retroviruses. 2007 Nov;23(11):1354-9. doi: 10.1089/aid.2007.0091. AIDS Res Hum Retroviruses. 2007. PMID: 18184077
Changes in hepatitis C viral response after initiation of highly active antiretroviral therapy and control of HIV viremia in chronically co-infected individuals.
Kottilil S, Jagannatha S, Lu A, Liu S, McLaughlin M, Metcalf JA, Dewar R, Campbell C, Koratich C, Maldarelli F, Masur H, Polis MA. Kottilil S, et al. Among authors: polis ma. HIV Clin Trials. 2004 Jan-Feb;5(1):25-32. doi: 10.1310/CVEU-980Q-MPRA-XRG8. HIV Clin Trials. 2004. PMID: 15002084 Clinical Trial.
Hepatitis B & hepatitis C in HIV-infection.
Kottilil S, Jackson JO, Polis MA. Kottilil S, et al. Among authors: polis ma. Indian J Med Res. 2005 Apr;121(4):424-50. Indian J Med Res. 2005. PMID: 15817955 Review.
Hepatic histologic response (HR) to combination therapy among HCV/HIV-coinfected individuals: interferon induces HR independent of sustained virologic response (SVR).
Wu L, Kottilil S, Lempicki R, Yang J, McLaughlin M, Hu Z, Koratich C, Reitano KN, Rehm CA, Masur H, Wood B, Kleiner DE, Polis MA. Wu L, et al. Among authors: polis ma. AIDS Res Hum Retroviruses. 2006 Nov;22(11):1091-8. doi: 10.1089/aid.2006.22.1091. AIDS Res Hum Retroviruses. 2006. PMID: 17147494 Clinical Trial.
HIV/Hepatitis C virus-coinfected virologic responders to pegylated interferon and ribavirin therapy more frequently incur interferon-related adverse events than nonresponders do.
Osinusi A, Rasimas JJ, Bishop R, Proschan M, McLaughlin M, Murphy A, Cortez KJ, Polis MA, Masur H, Rosenstein D, Kottilil S. Osinusi A, et al. Among authors: polis ma. J Acquir Immune Defic Syndr. 2010 Mar;53(3):357-63. doi: 10.1097/QAI.0b013e3181c7a29d. J Acquir Immune Defic Syndr. 2010. PMID: 20101190 Free PMC article. Clinical Trial.
Short communication: Interferon/ribavirin treatment for HCV is associated with the development of hypophosphatemia in HIV/hepatitis C virus-coinfected patients.
Funk EK, Shaffer A, Shivakumar B, Sneller M, Polis MA, Masur H, Heytens L, Nelson A, Kwan R, Kottilil S, Kohli A. Funk EK, et al. Among authors: polis ma. AIDS Res Hum Retroviruses. 2013 Sep;29(9):1190-4. doi: 10.1089/aid.2013.0035. Epub 2013 Jun 14. AIDS Res Hum Retroviruses. 2013. PMID: 23701022 Free PMC article.
177 results